Samsung BioLogics moves into the green in 2017
Samsung BioLogics, a biopharmaceutical unit of Korea’s top conglomerate, Samsung Group, posted an operating income last year, shifting from a loss a year earlier, the company said Wednesday.The total reached 63 billion won ($60 million) in 2017, compared to a 30.4 billion won loss reported a year earlier, the company said in a regulatory filing.
Sales also jumped 56.1 percent on-year to 459.8 billion won for the whole of last year, the company said.
Samsung BioLogics manufactures products for pharmaceutical brands such as Bristol-Myers Squibb and Roche Holding.
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)